drugset / Trial / NCT04324229

Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes

NCT04324229

Active not recruiting 80 enrolled Turku University Hospital
RandomizedParallel-groupSingle-blindPrevention

Summary

Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of T2D in obese women who have had gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or placebo group, once daily. Same laboratory tests are taken and instructions given at baseline 6 month and one year. After one year visits once a year until 5 years with same laboratory tests and measurements are taken.

Timeline

Start
2020-02-07
Primary completion
2024-09-30
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg Subcutaneous

Indications